Triglyceride-rich lipoprotein cholesterol and cardiovascular risk

Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease

(2023) Om P. Ganda   CURRENT OPINION IN LIPIDOLOGY

Is hypertriglyceridemia a reliable indicator of cholesterol-depleted apoB particles?

(2023) Davide De Marco et al.   Journal of Clinical Lipidology

Standardization of Apolipoprotein B, LDL‐Cholesterol, and Non‐HDL‐Cholesterol

(2023) John H. Contois et al.   Journal of the American Heart Association

Key Questions About Familial Hypercholesterolemia

(2022) Allan D. Sniderman et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Identification of Dysbetalipoproteinemia by an Enhanced Sampson-NIH Equation for Very Low-Density Lipoprotein-Cholesterol

(2022) Maureen Sampson et al.   Frontiers in Genetics

A Translational Tool to Facilitate Use of Apolipoprotein B for Clinical Decision-Making

(2022) Justine Cole et al.   CLINICAL CHEMISTRY

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

(2022) Aruna Das Pradhan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prioritizing the Role of Major Lipoproteins and Subfractions as Risk Factors for Peripheral Artery Disease

(2021) Michael G. Levin et al.   CIRCULATION

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society

(2021) Henry N Ginsberg et al.   EUROPEAN HEART JOURNAL

Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis

(2021) Nicholas A. Marston et al.   JAMA Cardiology

A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia

(2020) Maureen Sampson et al.   JAMA Cardiology

Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis

(2020) Tom G. Richardson et al.   PLOS MEDICINE

Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease

(2019) Brian A. Ference et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease: Data from UK Biobank

(2019) Claire Welsh et al.   CIRCULATION

Apolipoprotein B Particles and Cardiovascular Disease

(2019) Allan D. Sniderman et al.   JAMA Cardiology

Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding

(2018) Allan D. Sniderman et al.   JOURNAL OF LIPID RESEARCH

Type III Hyperlipoproteinemia: The Forgotten, Disregarded, Neglected, Overlooked, Ignored but Highly Atherogenic, and Highly Treatable Dyslipoproteinemia

(2018) Allan D. Sniderman   CLINICAL CHEMISTRY

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

Phenotypes of hypertriglyceridemia caused by excess very-low-density lipoprotein

(2012) Allan D. Sniderman et al.   Journal of Clinical Lipidology

Seven Direct Methods for Measuring HDL and LDL Cholesterol Compared with Ultracentrifugation Reference Measurement Procedures

(2010) W. G. Miller et al.   CLINICAL CHEMISTRY